Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

‘Zombie’ gene may protect elephants from cancer
Elephants possess an anti-cancer gene that can return from the dead.
Gene returns to life and kills cells with damaged DNA

A ‘zombie’ gene inherent in elephants may help to protect them against cancer, according to new research.

Humans and animals have one copy of the master suppressor gene, p53. The gene allows the body to recognise un-repaired DNA damage, a precursor of cancer, and causes those damaged cells to die.

But researchers at the Universities of Chicago and Utah recently found that elephants have 20 copies of p53. This makes their cells far more sensitive to damaged DNA and therefore quicker to die.

Now, new research reported in the journal Cell Reports details the second element of this process: an anti-cancer gene that can return from the dead.

“Genes duplicate all the time,” said Vincent Lynch, assistant professor of human genetics at the University of Chicago and the study’s senior author. “Sometimes they make mistakes, producing non-functional versions known as pseudogenes. We often refer to these dismissively as dead genes.”

While studying p53 in elephants, Lynch and his team discovered a former pseudogene - leukaemia inhibitory factor 6 (LIF6) - that had, by some means, evolved a new on-switch.

LIF6, which had returned from the dead, had become a valuable working gene. When activated by p53, its function is to respond to damaged DNA by killing the cell.

The LIF6 gene makes a protein that goes to the mitochondria, the cell’s main energy source. That protein pokes holes in the mitochondria, causing the cell to die.

“Hence, zombie,” said Lynch. “This dead gene came back to life. When it gets turned on by damaged DNA, it kills that cell, quickly. This is beneficial because it acts in response to genetic mistakes, errors made when the DNA is being repaired. Getting rid of that cell can prevent subsequent cancer.”

The researchers note that exactly how LIF6 triggers apoptosis remains unclear and will be the focus of future studies.

Become a member or log in to add this story to your CPD history

Applications open for MMI research grants

News Story 1
 RCVS' Mind Matters Initiative (MMI) has launched round two of its veterinary mental health research grants.

Researchers have until 11.59pm on Wednesday, 28 May 2025 to apply for a grant for research which reflects MMI's 2025 focus areas.

Only one Impact Grant was awarded last year, and so this year there are two Discovery Grants and one Impact Grants available. Each Discovery Grant is worth £5,000 and the Impact Grant is worth £15,000.

For more information or to apply, email researchgrants@rcvs.org.uk to contact the MMI team.

 

Click here for more...
News Shorts
BBC Radio 4 documentary addresses corporate fees

BBC Radio 4's File on 4 Investigates has released a documentary exploring how corporate-owned veterinary practices may be inflating bills to increase profit.

Released on 15 April, 'What's Happening To Your Vet Bills?' revealed the policies which many corporate groups have in place to increase their profits. This included targets and upgrades which veterinary teams are tasked with meeting on a regular basis.

It also features Anrich Vets, an independently-owned practice based in Wigan. Following the case of Staffordshire terrier Benjy, who is diagnosed with a tumour, the documentary shares how the team were able to offer contextualised care and advice to make the procedure as affordable as possible for his owners.

The documentary can be heard on demand on BBC iPlayer.